Drug Type Small molecule drug |
Synonyms Imidazoloacridine, Symadex, Symadex Pathfinder + [6] |
Target |
Mechanism FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors), Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | US | - | |
Breast Cancer | Phase 2 | - | - | |
Breast Cancer | Phase 2 | - | - | |
Breast Cancer | Phase 2 | - | - | |
Breast Cancer | Phase 2 | - | - | |
Colorectal Cancer | Phase 2 | - | - | |
Colorectal Cancer | Phase 2 | - | - | |
Colorectal Cancer | Phase 2 | GB | - | |
Colorectal Cancer | Phase 2 | - | - | |
Rheumatoid Arthritis | Phase 2 | US | - |
Phase 2 | 53 | mftdambpro(bdhhvubqjv) = wmunsjifvi agdzmfhzvf (wkexuvvdsk ) View more | - | 20 May 2008 | |||
Phase 1 | 36 | (zzkzusmuai) = fwxqzdichg cbikqzwtly (vmoerrrbtf ) View more | - | 20 May 2008 | |||
Phase 1 | 16 | (nkewdzhgss) = Grade 1 or 2 AEs most commonly reported as drug-related were nausea, asthenia, vomiting and diarrhea. jznwltzhsk (evehyufidv ) View more | - | 20 Jun 2006 |